Neuland Laboratories Limited share price
NSE: NEULANDLAB · ISIN INE794A01010
Key numbers
- Market cap
- ₹ 28,085 Cr
- Current price
- ₹ 21,890.00
- 52-week high / low
- ₹ 24,225 / 11,500
- Stock P/E
- 56.5
- Book value
- ₹ 1,461.0
- Dividend yield
- 0.16%
- ROCE
- 26.3%
- ROE
- 21.4%
- Debt to equity
- 0.16
- Sales growth (3 yrs)
- 18.5%
- Profit growth (3 yrs)
- 30.6%
- 1-year return
- 45.7%
About Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 293 | 514 | 440 | 776 | 642 |
| Operating profit | 34 | 156 | 77 | 307 | 223 |
| Net profit | 14 | 97 | 41 | 213 | 148 |
| EPS (₹) | 10.83 | 75.49 | 31.62 | 165.76 | 115.10 |
Concall summary (2026-08-10)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- The gross margin for the quarter was 61.2% as compared to 55.3% in Q1FY26, again, a function of our business mix during the quarter.
- Profit after tax for the quarter stood at INR147.4 crores as compared to INR13.7 crores in Q1FY26.
Growth & demand
- The total income for the quarter was INR650.1 crores as compared to INR300.6 crores in the corresponding quarter of the previous year, representing a growth of 16.3%.
- During the quarter, we also approved capital investments of approximately INR203 crores, of which INR196 crores is earmarked for strategic growth initiatives, largely related to capacity expansion at our Unit 1.
Margins & costs
- EBITDA for the quarter stood at INR231.1 crores with an EBITDA margin of 35.5%.
- This gross margin, as always, includes manufacturing expenses and other costs directly attributable to the product.
Capex & expansion
- As part of our investment, there was a cash outflow of INR121.6 crores towards capital expenditure during Q1FY27 , which was primarily driven by new R&D and peptide facilities.
- Against total approved capex of INR1,460 crores over the last 13 quarters, we have spent INR870 crores to date, with the balance committed towards projects under implementation.
Balance sheet & cash
- I will begin by taking you through the financial performance for the Q1FY27, followed by a brief update on working capital, capital expenditure and a few observations of the operating environment before handing over the call to Saharsh.
- The higher revenue base, operating leverage and the favorable customer mix contributed to the profitability profile during the quarter.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.